These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21777192)

  • 1. Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.
    Rowinsky EK; Schwartz JD; Zojwalla N; Youssoufian H; Fox F; Pultar P; Novosyadlyy R; Cosaert J; Ludwig DL
    Curr Drug Targets; 2011 Dec; 12(14):2016-33. PubMed ID: 21777192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
    Rowinsky EK; Youssoufian H; Tonra JR; Solomon P; Burtrum D; Ludwig DL
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5549s-5555s. PubMed ID: 17875788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.
    Attias-Geva Z; Bentov I; Ludwig DL; Fishman A; Bruchim I; Werner H
    Eur J Cancer; 2011 Jul; 47(11):1717-26. PubMed ID: 21450456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.
    Abou-Alfa GK; Capanu M; O'Reilly EM; Ma J; Chou JF; Gansukh B; Shia J; Kalin M; Katz S; Abad L; Reidy-Lagunes DL; Kelsen DP; Chen HX; Saltz LB
    J Hepatol; 2014 Feb; 60(2):319-24. PubMed ID: 24045151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
    Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
    Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Solomon VR; Alizadeh E; Bernhard W; Hartimath SV; Hill W; Chekol R; Barreto KM; Geyer CR; Fonge H
    Mol Pharm; 2019 Dec; 16(12):4807-4816. PubMed ID: 31518138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer.
    Solomon VR; Alizadeh E; Bernhard W; Makhlouf A; Hartimath SV; Hill W; El-Sayed A; Barreto K; Geyer CR; Fonge H
    Sci Rep; 2020 Oct; 10(1):18549. PubMed ID: 33122707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
    Shin DH; Lee HJ; Min HY; Choi SP; Lee MS; Lee JW; Johnson FM; Mehta K; Lippman SM; Glisson BS; Lee HY
    J Natl Cancer Inst; 2013 Oct; 105(20):1558-70. PubMed ID: 24092920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
    Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.
    Higano CS; Berlin J; Gordon M; LoRusso P; Tang S; Dontabhaktuni A; Schwartz JD; Cosaert J; Mehnert JM
    Invest New Drugs; 2015 Apr; 33(2):450-62. PubMed ID: 25749986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.
    Houghton PJ; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wu J; Smith MA
    Pediatr Blood Cancer; 2010 Jul; 54(7):921-6. PubMed ID: 20166202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
    Kalra N; Zhang J; Yu Y; Ho M; Merino M; Cao L; Hassan R
    Int J Cancer; 2012 Nov; 131(9):2143-52. PubMed ID: 22323052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.
    Gradishar WJ; Yardley DA; Layman R; Sparano JA; Chuang E; Northfelt DW; Schwartz GN; Youssoufian H; Tang S; Novosiadly R; Forest A; Nguyen TS; Cosaert J; Grebennik D; Haluska P
    Clin Cancer Res; 2016 Jan; 22(2):301-9. PubMed ID: 26324738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms.
    Zamykal M; Martens T; Matschke J; Günther HS; Kathagen A; Schulte A; Peters R; Westphal M; Lamszus K
    Neuro Oncol; 2015 Aug; 17(8):1076-85. PubMed ID: 25543125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
    Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody.
    Lee JS; Kang JH; Boo HJ; Hwang SJ; Hong S; Lee SC; Park YJ; Chung TM; Youn H; Mi Lee S; Jae Kim B; Chung JK; Chung Y; William WN; Kee Shin Y; Lee HJ; Oh SH; Lee HY
    Nat Commun; 2015 Oct; 6():8499. PubMed ID: 26465273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.